CDT Equity Inc. (CDT) vs Cellyan Biotechnology Co., Ltd (HKPD)
A side-by-side comparison of CDT Equity Inc. and Cellyan Biotechnology Co., Ltd across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CDT
CDT Equity Inc.
$0.88HealthcareDelayed quote: Oct 6, 2026, 2:57 PM EDT
HKPD
Cellyan Biotechnology Co., Ltd
$0.10HealthcareDelayed quote: Oct 6, 2026, 2:56 PM EDT
Total return — CDT vs HKPD
growth of $100 · dividends reinvested · last 2yCDT -100.0% (-99.9%/yr)HKPD -96.0% (-79.9%/yr)HKPD compounded faster over this window
Log scale — wide-divergence pair
CDT HKPD
CDT vs HKPD: by the numbers
- •HKPD is the larger company ($1M vs $674464 market cap).
- •CDT is profitable (6.30% net margin) while HKPD runs a net loss (-8.46%).
Metrics side by side
Valuation
| Metric | CDT | HKPD |
|---|---|---|
| P/S ratio | 0.00 | N/A |
| P/B ratio | 0.00 | 0.12 |
| EV / EBITDA | 4.13 | N/A |
Profitability
| Metric | CDT | HKPD |
|---|---|---|
| Gross margin | 0.00% | 10.32% |
| Operating margin | 0.00% | -7.41% |
| Net margin | 6.30% | -8.46% |
| ROE | 6.58% | -11.85% |
| ROIC | 4.47% | -9.45% |
Frequently asked
- Is CDT or HKPD more profitable?
- CDT runs the higher net margin — CDT at 6.30% versus HKPD at -8.46%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.